Literature DB >> 8096001

Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations.

R Blasczyk1, U Westhoff, H Grosse-Wilde.   

Abstract

CD4 and CD8 exist in membrane-bound and soluble forms. These antigens are the physiological ligands for molecules of HLA classes I and II, which we have found in soluble form in commercial immunoglobulin preparations. We measured concentrations of soluble CD4 and CD8, as well as soluble HLA-ABC and HLA-RQP in sixteen immunoglobulin preparations by enzyme immunosorbent assays. Only two preparations contained detectable CD8, and nine had soluble CD4 in varying amounts. There was great variation in concentrations of soluble HLA molecules. It is possible that the immunomodulating effects of immunoglobulin therapy in disorders with immune aetiology are due, at least partly, to these contaminating molecules.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096001     DOI: 10.1016/0140-6736(93)90563-v

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 2.  Interplay between T helper type 1 and type 2 cytokines and soluble major histocompatibility complex molecules: a paradigm in pregnancy.

Authors:  Irene Athanassakis; S Vassiliadis
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

Review 3.  Intravenous immunoglobulin and multiple sclerosis.

Authors:  Anat Achiron; Shmuel Miron
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Intravenous immunoglobulin and dendritic cells.

Authors:  Namita Misra; Jagadeesh Bayry; Jagadeesh Bayary; Sooryasarathi Dasgupta; Amal Ephrem; Jean-Paul Duong Van Huyen; Sandrine Delignat; Gazzala Hassan; Giuseppina Caligiuri; Antonino Nicoletti; Sebastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 5.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

6.  sHLA-I Contamination, a novel mechanism to explain ex vivo/in vitro modulation of IL-10 synthesis and release in CD8(+) T lymphocytes and in neutrophils following intravenous immunoglobulin infusion.

Authors:  Massimo Ghio; Paola Contini; Maurizio Setti; Gianluca Ubezio; Clemente Mazzei; Gino Tripodi
Journal:  J Clin Immunol       Date:  2010-02-02       Impact factor: 8.317

7.  Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients.

Authors:  B Vrugt; S Wilson; E van Velzen; A Bron; J K Shute; S T Holgate; R Djukanovic; R Aalbers
Journal:  Thorax       Date:  1997-07       Impact factor: 9.139

Review 8.  Intravenous immunoglobulin in neurological disorders: a mechanistic perspective.

Authors:  Namita Misra; Jagadeesh Bayry; Amal Ephrem; Suryasarathi Dasgupta; Sandrine Delignat; Jean-Paul Duong Van Huyen; Fabienne Prost; Sebastien Lacroix-Desmazes; Antonino Nicoletti; Michel D Kazatchkine; Srini V Kaveri
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

9.  High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.

Authors:  M Basta; M C Dalakas
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

Authors:  A Nicoletti; S Kaveri; G Caligiuri; J Bariéty; G K Hansson
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.